Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

L. Engelen, F. Persson, I. Ferreira, P. Rossing, P. Hovind, T. Teerlink, C.D.A. Stehouwer, H.H. Parving, C.G. Schalkwijk

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)3573-3577
JournalNephrology, Dialysis, Transplantation
Issue number11
Publication statusPublished - 2011

Cite this